Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.

Clinical lung cancer - 1 Nov 2020

Tsimberidou Apostolia M, Elkin Sheryl, Dumanois Robert, Pritchard Daryl

Abstract excerpt

Two recent studies examining the clinical and economic value of next-generation sequencing (NGS)-based diagnostic testing (multi-gene panel examining ≥ 30 genes) for non-small-cell lung cancer therapy compared with single gene ALK, EGFR testing to select therapy demonstrated statistically insignificant improvement in population-level overall survival and only a moderate incremental cost-effectiveness ratio...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Precision Medicine

Source

Identifiers

PMID: 32718774
DOI: 10.1016/j.cllc.2020.05.029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.PMID 32718774Read ↗

Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.Semantic proximity Read ↗

Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancerSemantic proximity Read ↗

Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.Semantic proximity Read ↗

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancerSemantic proximity Read ↗

Clinical next-generation sequencing in patients with non-small cell lung cancer.Semantic proximity Read ↗

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare HospitalSemantic proximity Read ↗

Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.Semantic proximity Read ↗

Application of next-generation sequencing to improve cancer management: A review of the clinical effectiveness and cost-effectiveness.Semantic proximity Read ↗

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.Semantic proximity Read ↗

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.Semantic proximity Read ↗

Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.